LHX2 Activators
LHX2 activators offers a rich diversity of compounds intricately fine-tuning the transcription factor LHX2, a linchpin in orchestrating pivotal developmental processes. Contrary to conventional expectations, these compounds, often classified as inhibitors, assert their influence through indirect mechanisms, becoming maestros within the intricate network of cellular signaling pathways that govern LHX2 activity. A prominent pathway in this chemical narrative is the modulation of Wnt signaling, exemplified by the elegant contributions of Wnt-C59 and XAV939. These compounds, acting as indirect activators, skillfully prevent the degradation of β-catenin, fostering its collaboration with LHX2 within the nucleus. This partnership enhances LHX2's transcriptional prowess, leaving an indelible mark on developmental processes, particularly during the intricate stages of embryogenesis and neurogenesis. The chemical ensemble further showcases LDN-193189, targeting BMP signaling, and SB431542, a TGF-β receptor inhibitor, as key players. By disrupting inhibitory signals from these pathways, these activators release constraints on LHX2, unleashing its potential in steering cellular differentiation and fate determination.
LHX2 and signaling pathways involving GSK-3, JNK, and PI3K/Akt, modulated by CHIR99021, JNK Inhibitor VIII, and LY294002, respectively. These compounds, with their indirect activation of LHX2 through the modulation of key kinases, illuminate the multifaceted nature of LHX2 regulation. An understanding of the nuances embedded within these compounds lays the groundwork for deciphering the complexities of LHX2-mediated developmental processes, providing valuable insights into potential interventions and advancing our comprehension of the intricacies in cellular orchestration.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021, a GSK-3 inhibitor, activates LHX2 indirectly. By inhibiting GSK-3, CHIR99021 stabilizes β-catenin, leading to its nuclear translocation. In the nucleus, β-catenin interacts with LHX2, promoting its transcriptional activity and influencing cellular processes such as embryonic development. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly activates LHX2 by blocking TGF-β signaling. Inhibition of TGF-β prevents the activation of Smad2/3, reducing their interaction with LHX2. This interruption in Smad2/3-mediated inhibition enhances LHX2 activity, impacting developmental processes. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII indirectly activates LHX2 by inhibiting JNK signaling. Reduced JNK activity alleviates its inhibitory effect on LHX2, allowing for enhanced LHX2 function and influence on cellular processes, particularly during neurogenesis. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, an AMPK inhibitor, indirectly activates LHX2. By inhibiting AMPK, Dorsomorphin modulates the mTOR pathway, influencing LHX2 activity. This connection plays a role in cellular processes, such as neural differentiation and embryonic development. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly activates LHX2 by inhibiting the JNK pathway. Reduced JNK activity alleviates its inhibitory effect on LHX2, allowing for enhanced LHX2 function and impact on cellular processes, including neural development. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
Wnt-C59 indirectly activates LHX2 by inhibiting the Wnt pathway. Inhibition of Wnt signaling prevents the degradation of β-catenin, leading to its nuclear translocation. In the nucleus, β-catenin interacts with LHX2, enhancing its transcriptional activity and influencing developmental processes. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189, a BMP receptor inhibitor, indirectly activates LHX2 by blocking BMP signaling. Inhibition of BMP prevents Smad1/5/8 activation, reducing their inhibitory effect on LHX2. This modulation enhances LHX2 activity, impacting developmental processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y27632, a ROCK inhibitor, indirectly activates LHX2 by inhibiting ROCK signaling. Reduced ROCK activity affects downstream pathways, influencing LHX2 function and impacting cellular processes, particularly during neural differentiation. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 indirectly activates LHX2 by inhibiting the Wnt pathway. Inhibition of Wnt signaling prevents β-catenin degradation, leading to its nuclear translocation. In the nucleus, β-catenin interacts with LHX2, enhancing its transcriptional activity and influencing developmental processes. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, a CaMKII inhibitor, indirectly activates LHX2 by modulating the CaMKII pathway. Inhibition of CaMKII impacts downstream signaling, influencing LHX2 function and contributing to cellular processes, particularly during neural differentiation. | ||||||